Related Experiment Videos
COLAL-PRED Alizyme.
Stephen B Hanauer1, Miles Sparrow
1University of Chicago Medical Center, Department of Medicine, Gastroenterology & Nutrition, MC 9028, 5841 S Maryland Avenue, Chicago, IL 60637, USA. shanauer@medicine.bsd.uchicago.edu
Current Opinion in Investigational Drugs (London, England : 2000)
|December 3, 2004
Summary
COLAL-PRED is a novel colon-targeted drug delivery system for inflammatory bowel disease treatment. Alizyme is advancing this potential therapy into Phase III clinical trials, indicating promising developments in IBD management.
Area of Science:
- Gastroenterology
- Pharmacology
- Drug Delivery Systems
Background:
- Inflammatory bowel disease (IBD) presents significant treatment challenges.
- Current therapies may have systemic side effects or limited efficacy.
- Targeted drug delivery aims to improve therapeutic outcomes and reduce adverse events.
Purpose of the Study:
- To introduce COLAL-PRED, a colon-targeted formulation of prednisolone sodium metasulfobenzoate.
- To highlight the COLAL colonic drug delivery technology enabling targeted delivery.
- To report on the developmental stage and upcoming clinical trials for IBD.
Main Methods:
- Development of COLAL-PRED utilizing the COLAL colonic drug delivery technology.
- Formulation designed for targeted release in the colon.
- Planning and initiation of Phase III clinical trials.
Main Results:
- COLAL-PRED demonstrates potential for targeted delivery of prednisolone to the colon.
- The COLAL technology facilitates site-specific drug release.
- Successful progression to Phase III trials signifies promising preclinical and early clinical data.
Conclusions:
- COLAL-PRED represents a targeted therapeutic approach for inflammatory bowel disease.
- The COLAL drug delivery technology offers a platform for colon-specific treatments.
- Advancement to Phase III trials underscores the potential of COLAL-PRED in IBD management.